我国医药产业发展态势分析及展望

Analysis and Prospect of the Pharmaceutical Industry Development Trend in China

医药产业发展是保障人民生命健康的基石。本文较为全面深入地比较了国内外医药产业的发展态势,分析指出医药产业市场全球总规模及在各国的战略地位正不断提升,同时我国医药产业发展前景广阔,潜在市场空间大。在此基础上,进一步梳理探讨我国医药产业发展前景及驱动因素,包括人口结构改变及健康意识的提高、全球竞争性压力增加、政府对医药产业的持续投入以及头部企业研发投入自主加大。而后,文章从医疗实践角度出发,就精准性、安全性、时效性、可负担性和政策保障性五个方面提出了医药产业面临的挑战。进一步对应面临的挑战,提出了针对性的对策建议。研究提出,要集中力量建设并维护精细化大型人群队列及数据平台;抓紧推动我国国际领先的前沿技术领域发展,并支持其研发转化,推动其占据医药研发原始创新高地;推动医药研发产业化进程和推广应用,在研发和临床实验阶段鼓励“产学研”结合、在评审阶段增强同技术发展相符的评审能力、在促进创新产品推广阶段增强知识产权等保障服务能力;面对医疗应用,需要完善多层级医疗保障渠道,从患者实际需求出发减轻患者自费负担;对于整体行业而言,需要增强政策保障全链条性及实施效率,有效激发医疗行业的发展动力。以期为我国医药产业后续投入、政策制定和发展决策提供参考依据。

The development of the pharmaceutical industry is the cornerstone for safeguarding people’s lives and health.This study is based on a macro perspective and provides a comprehensive and in-depth comparison of the development trend of the pharmaceutical industry in China and abroad.It is pointed out that the global market size and strategic position of the pharmaceutical industry in various countries are constantly improving.Meanwhile,the development prospect of China’s pharmaceutical industry is broad,and the potential market space is large.On this basis,we further explore the development prospects and driving factors of China’s pharmaceutical industry,including changes in population structure and increased health awareness,increasing global competitive pressure,sustained government investment and support for the pharmaceutical industry,and increase in research and development(R&D)investment by leading enterprises.Moreover,from the perspective of medical practice,we propose the challenges faced by the pharmaceutical industry in five aspects:precision,safety,timeliness,affordability,and policy guarantee.Furthermore,in response to the challenges we face,we propose the following targeted countermeasures:(1)building and maintaining a refined large-populationbased cohort and data platform while providing sustained support;(2)accelerating the R&D and transformation of China’s internationally leading technologies in the pharmaceutical industry to strengthen original innovation and seize the market;(3)promoting the industrialization of pharmaceutical R&D by encouraging industry–education–research integration in the R&D and clinical trials stage,strengthening the evaluation ability in the evaluation stage,and improving guarantee services such as intellectual property protection in the promotion stage of innovative products;(4)improving multi-level medical security channels to strive for more sources of support and reduce the burden of self-payment for patients;and(5)enhancing the full chain of policy protection and implementation efficiency to effectively stimulate the development momentum of the medical industry.This study aims to provide a reference for the subsequent investment,policy formulation,and development decisions of China’s pharmaceutical industry.